title: Mechanisms involved in the regional haemodynamic effects of intermedin (adrenomedullin 2) compared with adrenomedullin in conscious rats.
abstract: OBJECTIVE
  Intermedin (IMD) is a newly identified member of the calcitonin family of peptides that shares structural and functional homology with adrenomedullin (AM). In vivo cardiovascular effects of AM have been described, but relatively little is known of the in vivo actions of IMD. The purpose of this study was to compare the regional haemodynamic effects of IMD with those of AM in conscious rats, and investigate possible underlying mechanisms.
  
  
  METHODS
  Measurements of blood pressure, heart rate and renal, mesenteric and hindquarters haemodynamics were made in conscious, chronically-instrumented rats.
  
  
  RESULTS
  IMD caused tachycardia and vasodilatation in all three vascular beds, associated with modest hypotension. At an equimolar dose (1 nmol.kg(-1)), most of the cardiovascular effects of IMD were greater than those of AM. The AM receptor antagonist, AM(22-52), was equally effective in attenuating the renal and mesenteric vasodilator effects of IMD (1 nmol.kg(-1)) and AM (3 nmol.kg(-1)), but inhibition of NO synthase was more effective at reducing the vasodilator effects of IMD than AM. Vascular K(ATP) channel blockade with U-37883A did not inhibit the vasodilator effects of either peptide.
  
  
  CONCLUSIONS
  In vivo, the regional haemodynamic profile of IMD resembles that of AM, and some of the vasodilator effects of IMD are mediated by AM receptors and NO, but not by K(ATP) channels. The cardiovascular effects of AM have been implicated in various pathological conditions, but whether or not endogenous IMD fulfils a similar role remains to be determined.
authors.affiliation: Centre for Integrated Systems Biology & Medicine, School of Biomedical Sciences, University of Nottingham, Nottingham, UK.
authors.forename: L
authors.initials: L
authors.lastname: Jolly
authors.forename: J E
authors.initials: JE
authors.lastname: March
authors.forename: P A
authors.initials: PA
authors.lastname: Kemp
authors.forename: T
authors.initials: T
authors.lastname: Bennett
authors.forename: S M
authors.initials: SM
authors.lastname: Gardiner
mesh_terms: D053607:Adrenomedullin / Q000494:pharmacology / Q000502:physiology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D007022:Hypotension / Q000139:chemically induced; D007668:Kidney / Q000098:blood supply / Q000187:drug effects; D008297:Male; D009479:Neuropeptides / Q000494:pharmacology / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000187:drug effects; D013152:Splanchnic Circulation / Q000187:drug effects; D013610:Tachycardia / Q000139:chemically induced; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: C499411:Adm2 protein, rat; D009479:Neuropeptides; D014665:Vasodilator Agents; D053607:Adrenomedullin
references.citation: Peptides. 2006 Jun;27(6):1390-6
references.pmid: 16412533
references.citation: Eur J Pharmacol. 2004 Aug 16;497(1):75-80
references.pmid: 15321737
references.citation: Physiol Rev. 2004 Jul;84(3):903-34
references.pmid: 15269340
references.citation: Endocrinology. 2007 Apr;148(4):1727-35
references.pmid: 17218418
references.citation: J Cardiovasc Pharmacol. 2000 Oct;36(4):526-32
references.pmid: 11026656
references.citation: Peptides. 2005 Sep;26(9):1640-6
references.pmid: 16112404
references.citation: Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H1120-7
references.pmid: 16227344
references.citation: Stroke. 1997 Jan;28(1):181-5
references.pmid: 8996509
references.citation: Peptides. 2006 Jan;27(1):74-9
references.pmid: 16023765
references.citation: J Biol Chem. 2004 Feb 20;279(8):7264-74
references.pmid: 14615490
references.citation: J Pharmacol Exp Ther. 2005 Jan;312(1):53-60
references.pmid: 15328375
references.citation: Br J Pharmacol. 2008 Mar;153 Suppl 2:S1-209
references.pmid: 18347570
references.citation: Clin Exp Pharmacol Physiol. 2002 Mar;29(3):229-32
references.pmid: 11906489
references.citation: Br J Pharmacol. 1995 Feb;114(3):584-91
references.pmid: 7735684
references.citation: Nature. 1998 May 28;393(6683):333-9
references.pmid: 9620797
references.citation: Hypertension. 1997 May;29(5):1148-55
references.pmid: 9149680
references.citation: Am J Physiol. 1997 Jan;272(1 Pt 2):R234-42
references.pmid: 9039014
references.citation: Life Sci. 1991;48(8):733-9
references.pmid: 1994182
references.citation: Br J Pharmacol. 2003 Oct;140(3):477-86
references.pmid: 12970090
references.citation: Br J Pharmacol. 1999 Aug;127(7):1611-8
references.pmid: 10455317
references.citation: Biochem Biophys Res Commun. 2006 Mar 10;341(2):567-72
references.pmid: 16434024
references.citation: Biochem Biophys Res Commun. 2003 Nov 28;311(4):1072-7
references.pmid: 14623291
references.citation: Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H2620-6
references.pmid: 11087213
references.citation: Eur J Pharmacol. 2007 Mar 8;558(1-3):128-32
references.pmid: 17204266
references.citation: J Surg Res. 1997 Feb 1;67(2):163-8
references.pmid: 9073563
references.citation: Br J Pharmacol. 2008 Mar;153 Suppl 1:S247-62
references.pmid: 17965749
references.citation: J Pharmacol Exp Ther. 1993 Aug;266(2):655-65
references.pmid: 8355199
references.citation: Comput Biol Med. 1987;17(2):85-99
references.pmid: 3581810
references.citation: J Cardiovasc Pharmacol. 1998 Jun;31(6):894-903
references.pmid: 9641474
references.citation: Endocrinology. 2006 Apr;147(4):1871-7
references.pmid: 16410298
references.citation: Br J Pharmacol. 1995 Jul;115(6):917-24
references.pmid: 7582521
references.citation: J Mol Neurosci. 2008 Jul;35(3):355-61
references.pmid: 18418734
references.citation: Am J Physiol Regul Integr Comp Physiol. 2005 Apr;288(4):R919-27
references.pmid: 15576658
references.citation: Proc West Pharmacol Soc. 2007;50:43-6
references.pmid: 18605227
references.citation: Peptides. 2008 Aug;29(8):1321-8
references.pmid: 18538894
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2006 Aug;373(5):376-80
references.pmid: 16736153
references.citation: Biochem Biophys Res Commun. 2005 Feb 18;327(3):713-9
references.pmid: 15649405
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1998 Aug;358(2):245-52
references.pmid: 9750011
references.citation: FEBS Lett. 2004 Jan 2;556(1-3):53-8
references.pmid: 14706825
references.citation: Clin Exp Pharmacol Physiol. 2004 Dec;31 Suppl 2:S49-50
references.pmid: 15649289
references.citation: Peptides. 2000 Feb;21(2):257-63
references.pmid: 10764954